Table 2.
Paradigms tested for chronic electrographic features
| Paradigm | KA (m/k, i.p.) | VPA (m/k, i.p.) | N | Total Dose 1 (mg/kg, i.p.) | SE induction % (N) | Mortality 2 % (N) | SRS |
|---|---|---|---|---|---|---|---|
| Ex-KA/VPA | 10→5→2.5x | 300 | 7 | 20-22.5 | 100% (7) | 29% (2) | 0% (0) |
| Ex-KA/NaCl | 10→5→2.5x | -- | 9 | 17.5-25.0 | 89% (8) | 0% (0) | 0% (0) |
| 5 mg/kg | 5x | -- | 14 | 20-30 | 71% (10) | 21% (3) | 14% (2) |
Kainate, KA; VPA, valproic acid; SRS, spontaneous, recurrent seizures;
‘x’ denotes repeated KA injections (i.p.) every 20 minutes until the first Racine stage 4/5 seizure was observed
1
Total Dose is the aggregate dose of KA administered before first seizure
2
Mortality encompasses a 7-8 week period of observation